Wall Street analysts forecast that Illumina (ILMN) will report quarterly earnings of $0.91 per share in its upcoming release, pointing to a year-over-year increase of 550%. It is anticipated that revenues will amount to $1.08 billion, exhibiting a decline of 4.1% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.8% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estim ...

Core Viewpoint - Illumina is expected to report a year-over-year increase in earnings despite a decline in revenues, with the consensus outlook indicating a significant earnings surprise potential [1][3][11]. Earnings Expectations - The upcoming earnings report is anticipated to show earnings of $0.91 per share, reflecting a year-over-year increase of +550%, while revenues are projected to be $1.08 billion, down 4.1% from the previous year [3][17]. - The earnings report is scheduled for release on February 6, 2025, and could influence stock movement based on whether the results exceed or fall short of expectations [2][12]. Estimate Revisions - The consensus EPS estimate has been revised 0.84% higher in the last 30 days, indicating a positive reassessment by analysts [4][10]. - Illumina's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +1.11%, suggesting a strong likelihood of beating the consensus EPS estimate [10][11]. Earnings Surprise History - Illumina has a history of exceeding consensus EPS estimates, having beaten expectations in the last four quarters, including a +31.03% surprise in the most recent quarter [12][13]. - The company's past performance in matching or exceeding estimates may influence future earnings expectations [12]. Industry Comparison - GSK, another player in the biomedical and genetics industry, is expected to report earnings of $0.53 per share, indicating a year-over-year decline of -26.4%, with revenues projected at $10 billion, unchanged from the previous year [17][18]. - GSK's Earnings ESP is -9.86%, combined with a Zacks Rank of 4 (Sell), making it challenging to predict an earnings beat [18].

Core Insights - Illumina is well-positioned to continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates significantly in the last two quarters [1][2] - The company reported earnings of $1.14 per share for the last quarter, exceeding the Zacks Consensus Estimate of $0.87 per share by 31.03%, and previously reported earnings of $0.36 per share against an estimate of $0.12 per share, resulting in a 200% surprise [2] Earnings Performance - Illumina has an average earnings surprise of 115.52% over the last two quarters, indicating strong performance [1] - Recent estimates for Illumina have been revised upwards, contributing to a positive Earnings ESP of +1.94%, suggesting bullish sentiment among analysts regarding the company's earnings prospects [3][6] Predictive Metrics - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data indicating that nearly 70% of stocks with this combination produce positive surprises [4][6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which are often more accurate [5] Upcoming Earnings Report - Illumina's next earnings report is expected to be released on February 6, 2025, and the current positive indicators suggest a favorable outlook for the company [6]

Illumina, Inc. (ILMN) has announced a collaboration with NVIDIA (NVDA) to advance technology platforms for analyzing and interpreting multiomic data. By combining advancements in artificial intelligence (AI) with multiomic data at scale, the partnership seeks to optimize the analysis of vast amounts of data involved in multiomic research.The latest development aims to accelerate progress in clinical research, genomics AI development and drug discovery.ILMN Stock’s Trend in Response to the NewsFollowing the ...

Key Points Company and Industry Overview - **Company**: Illumina, Inc. (NASDAQ: ILMN) - **Industry**: Life Science Tools and Diagnostics - **Event**: 43rd Annual JPMorgan Healthcare Conference Call - **Date**: January 14, 2025 - **Time**: 12:00 PM ET - **Participants**: Jacob Thaysen (CEO), Ankur Dhingra (CFO), Rachel Vatnsdal (JPMorgan) - **Duration**: 40 minutes (20 minutes presentation, 20 minutes Q&A) - **Focus**: Business overview, financial results, strategic direction, and future outlook Core Points and Arguments - **Business Growth**: Illumina has been pioneering next-generation sequencing (NGS) technology for over 25 years, making it a foundational tool in genomic research and clinical applications worldwide. - **Global Strength**: Illumina is operating from a position of global strength, with significant market presence and influence. - **2024 Results**: Preliminary Q4 and full year 2024 results will be covered, along with outlook for 2025. - **New Strategy**: Illumina is shifting its focus from cost per gigabase to providing the highest quality insights at the lowest end-to-end cost. - **Excitement for Future**: The company is incredibly excited about the path ahead and the opportunities it presents. Other Important Points - **Forward-Looking Statements**: The presentation includes forward-looking statements and non-GAAP measures, which are detailed in Illumina's SEC filing. - **Presentation Structure**: The presentation will cover four main areas: business overview, financial results, strategic direction, and future outlook. - **Q&A Session**: Approximately 20 minutes of the session will be dedicated to answering questions from participants.

Core Insights - Illumina is positioned strongly in the next-generation sequencing (NGS) market, which has evolved into a critical tool for genomic research and clinical applications globally [5]. Group 1: Business Overview - Illumina has pioneered the growth of NGS over the past 25 years, transforming it from a nascent technology to a foundational tool in biology [5]. - The company is optimistic about the significant opportunities ahead, indicating a robust outlook for future growth [4]. Group 2: Financial Performance - Preliminary results for Q4 and full year 2024 will be discussed, along with insights into the outlook for 2025 [4]. - The company aims to transition from focusing on cost per gigabase to delivering the highest quality insights at the lowest end-to-end cost [4]. Group 3: Strategic Progress - Illumina has made strong progress against its new strategy, emphasizing quality and cost efficiency in its offerings [4]. - The company expresses excitement about the path ahead, highlighting confidence in its strategic direction [4].

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2024 and preliminary outlook for fiscal year 2025 ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com. Core Illumina Revenue of approxi ...

Partnership Overview - Illumina and NVIDIA are collaborating to combine AI advancements with multiomic data at scale, leveraging Illumina's sequencing technology and NVIDIA's AI tools to accelerate drug discovery and clinical development [1][8] - The partnership aims to integrate NVIDIA's RAPIDS™ accelerated data science software, BioNeMo™ platform, and MONAI for spatial cell imaging workflows with Illumina's Connected Analytics platform [2] - The collaboration will enable DRAGEN algorithms on NVIDIA GPUs and incorporate NVIDIA's image processing and single-cell tertiary analysis tools into Illumina's multiomics module [3] Technological Integration - Illumina's DRAGEN-powered multiomics offerings, genomics AI tools, and Connected Analytics platform have streamlined genomic data generation and analysis [10] - NVIDIA's AI and data science tools will be integrated with Illumina's sequencing and analytics platforms to drive the next generation of genomics interpretation [3] - Customers will be able to leverage NVIDIA's biology foundation models with their proprietary datasets for tasks such as cell state or gene transcription prediction [5] Industry Impact - The collaboration aims to democratize genomics for drug discovery through AI-powered insights, enabling deeper biological insights and total workflow solutions for customers [3] - The partnership is expected to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research and genomics AI development [8] - Illumina's investment in AI for genomic interpretation includes leading algorithms such as SpliceAI, PrimateAI-3D, and Emedgene xAI [10]

Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep™, powered by SOMAmer® ...

SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2024 following the close of market on Thursday, February 6, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call D ...